NEW YORK (GenomeWeb) – GenMark Diagnostics said today that it has increased the size of its previously announced public offering to 6,382,978 shares of its common stock price at $11.75 per share.

The gross proceeds to GenMark, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be about $75.0 million.

JP Morgan and Bank of America Merrill Lynch are joint book-running managers for the offering. William Blair, Cowen, and Raymond James are co-managers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.